The firm will begin a verification study later this month using its cell-sorting platform and molecular analysis tool on patients with a pelvic mass scheduled for surgery.
The team believes users could apply the technology, combined with a predictive risk score, to complement imaging tools to screen for cancers in the clinical space.
The group will start a pilot study at Columbia University next week to sequence genes from 600 Parkinson's disease patients before expanding to a larger cohort.
The British team believes its classifier can identify men who will need treatment within five years, minimizing the need of repeated checkups for low-risk patients.
The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.
The University of Arkansas researchers aim to commercialize the Cytophone platform, in development since 2003, by launching a startup in the next year.
By examining metagenomic data of bacterial species in a patient's gut, the researchers aim to improve diagnosis and long-term nutritional intervention and treatment.
The microfluidic immunoassay uses spectrometry and a lateral flow method to diagnose the "very large global health problem" in about 20 minutes.
The iPod-sized system integrates a microcontroller, a peristaltic pump, heparin injector, and microfluidic chip to capture tumor cells in a patient's bloodstream.
OncoCell aims to enter the cancer prognostic space with its noninvasive immuno-genomics RNA transcriptomics prognostic platform to help differentiate patients with aggressive forms of prostate cancer from patients with indolent disease.